Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous human insulin in the therapy of adult subjects with type 1 or type 2 diabetes mellitus and chronic asthma: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial

Next Previous
Trial Profile

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous human insulin in the therapy of adult subjects with type 1 or type 2 diabetes mellitus and chronic asthma: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Pfizer

    • Most Recent Events

    • 14 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
    • 15 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008, based on information from ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top